[Comment] Very low LDL-cholesterol concentrations achieved: which target is next?

It has been a long and winding road towards acceptance of LDL cholesterol as a pivotal and causal factor in the development of atherosclerosis and cardiovascular disease. The evidence was first derived from experimental, epidemiological, and genetic studies, as well as from clinical trials with statins and ezetimibe.1 The Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk (FOURIER) trial2 extended the body of evidence, showing that evolocumab, a fully human proprotein convertase subtilisin-kexin type 9 (PCSK9) monoclonal antibody, when added to conventional lipid-lowering therapy, not only lowered LDL cholesterol to extremely low concentrations but also had a beneficial effect on cardiovascular disease risk.

Source: LANCET - August 28, 2017 Category: General Medicine Authors: G Kees Hovingh, S Matthijs Boekholdt, Erik S Stroes Tags: Comment Source Type: research